金吾财讯 | 同源康医药(02410)宣布其治疗EGFR突变肺癌脑转移药物关键II期临床达到研究预期。早盘股价表现亮眼，一度大幅抽升50.65%，至46.1港元，随后升幅有所回落，目前暂升26.47%，报38.7港元。此次备受关注的是公司自主研发的TY-9591(商品名：卡达沙)对比奥希替尼(商品名：泰瑞沙)作为一线治疗EGFR突变肺癌脑转移的关键II期临床试验。根据研究者数据显示，该试验取得了具有统计学显着意义和重大临床获益的成果。其主要研究终点颅内客观缓解率(iORR)达到预期目标，TY-9591与奥希替尼相比，显示出了在统计学上具有显着意义以及在临床上具有明显改善的优势，并且无论在全人群还是在不同亚组人群(涵盖基因分型、颅内病灶个数、ECOG评分等方面)中，均呈现出明显的统计学差异。鉴于此次临床试验的积极结果，同源康医药计划在近期向国家药品监督管理局药品审评中心(CDE)提交新药上市申请(NDA)。这一进展不仅为公司自身的发展带来了新的机遇，也有望为EGFR突变肺癌脑转移患者提供更有效的治疗选择，引发了市场的广泛关注和积极反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.